Becton, Dickinson and Company (NYSE:BDX) EVP Michael David Garrison Sells 1,100 Shares

Becton, Dickinson and Company (NYSE:BDX) EVP Michael David Garrison sold 1,100 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total transaction of $160,226.00. Following the transaction, the executive vice president directly owned 13,172 shares of the company’s stock, valued at approximately $1,918,633.52. This trade represents a 7.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael David Garrison also recently made the following trade(s):

• On Wednesday, June 10th, Michael David Garrison sold 1,100 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $151.48, for a total transaction of $166,628.00.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock opened at $151.25 on Friday. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $187.35. The company has a market capitalization of $41.67 billion, a price-to-earnings ratio of 38.29, a PEG ratio of 10.46 and a beta of 0.22. The company has a 50-day simple moving average of $148.15 and a 200 day simple moving average of $170.85. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.94.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.13. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The firm had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.67 billion. During the same period last year, the business posted $3.35 earnings per share. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, sell-side analysts predict that Becton, Dickinson and Company will post 12.61 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th will be issued a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend is Tuesday, June 9th. Becton, Dickinson and Company’s dividend payout ratio is currently 106.33%.

Analyst Ratings Changes

BDX has been the subject of a number of recent research reports. Royal Bank Of Canada set a $175.00 target price on shares of Becton, Dickinson and Company in a research report on Tuesday, April 14th. Wells Fargo & Company lifted their price objective on shares of Becton, Dickinson and Company from $157.00 to $161.00 and gave the stock an “equal weight” rating in a research note on Friday, May 8th. Weiss Ratings lowered shares of Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. TD Cowen dropped their price target on shares of Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating for the company in a research report on Monday, May 4th. Finally, Zacks Research upgraded Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a research note on Friday, April 10th. Seven research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $181.00.

Institutional Trading of Becton, Dickinson and Company

Several hedge funds have recently modified their holdings of the stock. Brighton Jones LLC lifted its stake in Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after acquiring an additional 877 shares during the period. Graybill Wealth Management LTD. increased its stake in shares of Becton, Dickinson and Company by 47.3% during the third quarter. Graybill Wealth Management LTD. now owns 27,592 shares of the medical instruments supplier’s stock valued at $5,164,000 after purchasing an additional 8,859 shares in the last quarter. Skba Capital Management LLC lifted its holdings in shares of Becton, Dickinson and Company by 1,619.9% during the third quarter. Skba Capital Management LLC now owns 57,514 shares of the medical instruments supplier’s stock valued at $10,765,000 after purchasing an additional 54,170 shares during the last quarter. Danske Bank A S bought a new position in shares of Becton, Dickinson and Company during the third quarter valued at $34,596,000. Finally, Elo Mutual Pension Insurance Co increased its position in shares of Becton, Dickinson and Company by 24.7% during the third quarter. Elo Mutual Pension Insurance Co now owns 34,609 shares of the medical instruments supplier’s stock valued at $6,478,000 after acquiring an additional 6,856 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.